Evidence map›Paper›PMID 21515659›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2011

Death receptors mediate the adverse effects of febrile-range hyperthermia on the outcome of lipopolysaccharide-induced lung injury.

Anne B Lipke, Gustavo Matute-Bello, Raquel Herrero, Venus A Wong, Stephen M Mongovin, Thomas R Martin

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03376854 phase2withdrawnnot on this mapstarted 2018, after this paper: background citation

Pilot Randomized Clinical Trial of Therapeutic Hypothermia Plus Neuromuscular Blockade vs. Standard of Care in COVID-19 Patients With Moderate to Severe ARDS - the Cooling to Help Injured Lungs (CHILL) Pilot Study

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2018 to 2021Enrolled0ConditionsRespiratory Distress Syndrome, Adult, Sars-CoV2ArmsHypothermia, Neuromuscular Blocking Agents, Standard of Care
NCT04545424 phase2recruitingnot on this mapstarted 2021, after this paper: background citation

Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients With ARDS

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2021 to 2026Enrolled340ConditionsRespiratory Distress Syndrome, AdultArmsHypothermia, Neuromuscular Blocking Agents, Standard of care
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Exposure to febrile-range hyperthermia potentiates Wnt signalling and epithelial-mesenchymal transition gene expression in lung epithelium.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2018
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anne B LipkeDivision of Pulmonary and Critical Care Medicine, Puget Sound Medical Center, University of Washington, Seattle, Washington 98108, USA. ablipke@u.washington.edu
Gustavo Matute-Bello
Raquel Herrero
Venus A Wong
Stephen M Mongovin
Thomas R Martin
Pulmonary and Critical Care Associates · USUniversity of Puget Sound · US

Funding

The alveolar epithelium in lung injury and repairR01HL083044 · NHLBI · UNIVERSITY OF WASHINGTON · PI MATUTE-BELLO, GUSTAVO · 2006 to 2010
$2.3M
Acute Lung Injury: Link Between Apoptosis and Fibrosis R01HL081764 · NHLBI · UNIVERSITY OF WASHINGTON · PI MATUTE-BELLO, GUSTAVO · 2007 to 2011
$1.6M
Mechanisms of enhanced lung epithelial injury in febrile hyperthermiaF32HL096348 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIPKE, ANNE B · 2009 to 2010
$119k
NHLBI NIH HHS HL081764NHLBI NIH HHS HL083044NHLBI NIH HHS HL096348NHLBI NIH HHS R01 HL081764
6 · The paper itself

Abstract

We have shown that febrile-range hyperthermia enhances lung injury and mortality in mice exposed to inhaled LPS and is associated with increased TNF-α receptor activity, suppression of NF-κB activity in vitro, and increased apoptosis of alveolar epithelial cells in vivo. We hypothesized that hyperthermia enhances lung injury and mortality in vivo by a mechanism dependent on TNF receptor signaling. To test this, we exposed mice lacking the TNF-receptor family members TNFR1/R2 or Fas (TNFR1/R2(-/-) and lpr) to inhaled LPS with or without febrile-range hyperthermia. For comparison, we studied mice lacking IL-1 receptor activity (IL-1R(-/-)) to determine the role of inflammation on the effect of hyperthermia in vivo. TNFR1/R2(-/-) and lpr mice were protected from augmented alveolar permeability and mortality associated with hyperthermia, whereas IL-1R(-/-) mice were susceptible to augmented alveolar permeability but protected from mortality associated with hyperthermia. Hyperthermia decreased pulmonary concentrations of TNF-α and keratinocyte-derived chemokine after LPS in C57BL/6 mice and did not affect pulmonary inflammation but enhanced circulating markers of oxidative injury and nitric oxide metabolites. The data suggest that hyperthermia enhances lung injury by a mechanism that requires death receptor activity and is not directly associated with changes in inflammation mediated by hyperthermia. In addition, hyperthermia appears to enhance mortality by generating a systemic inflammatory response and not by a mechanism directly associated with respiratory failure. Finally, we observed that exposure to febrile-range hyperthermia converts a modest, survivable model of lung injury into a fatal syndrome associated with oxidative and nitrosative stress, similar to the systemic inflammatory response syndrome.

Indexed as

Hyperthermia, InducedAnimalsApoptosisChemokinesfas ReceptorInterleukin-1LipopolysaccharidesLungLung InjuryMiceMice, Inbred C57BLPneumoniaReceptors, Death DomainReceptors, Interleukin-1Receptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIChemokinesFas protein, mousefas ReceptorInterleukin-1keratinocyte-derived chemokinesLipopolysaccharidesReceptors, Death DomainReceptors, Interleukin-1Receptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITumor Necrosis Factor-alpha

Identifiers

PMID21515659
PMCPMC3129896
OpenAlexW2146705487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.